A menu-driven facility for sample-size calculation in novel multiarm, multistage randomized controlled trials with a time-to-event outcome

Stata Journal

Volumn 9, Issue 4, 2009, Pages 505-523

  Barthel, Friederike M S ^a   Royston, Patrick ^b   Parmar, Mahesh K B ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Multiple arms; Multistage trial; Nstage; Nstagemenu; Randomized controlled trial; St0175; Surrogate marker; Survival analysis

Indexed keywords

EID: 65649143808     PISSN: 1536867X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1536867x0900900401     Document Type: Article

References (9)

1. Barthel, F. M.-S., M. K. B. Parmar, and P. Royston. 2009. How do multi-stage, multiarm trials compare to the traditional two-arm parallel group design - a reanalysis of 4 trials. Trials 10: 21-31.
2. Bookman, M. A., for the Gynecologic Cancer InterGroup (GCIG). 2006. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. 2006 ASCO Annual Meeting Proceedings Part I. Journal of Clinical Oncology 24(18S): 5002.
3. Buyse, M., and G. Molenberghs. 1998. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54: 1014-1029.
4. International Collaborative Ovarian Neoplasm (ICON) Group. 2002. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet 360: 505-515.
5. McGuire, W. P., W. J. Hoskins, M. F. Brady, P. R. Kucera, E. E. Partridge, K. Y. Look, D. L. Clarke-Pearson, and M. Davidson. 1996. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine 334: 1-6.
6. Parmar, M. K. B., F. M.-S. Barthel, M. Sydes, R. Langley, R. Kaplan, E. Eisenhauer, M. Brady, N. James, M. A. Bookman, A.-M. Swart, W. Qian, and P. Royston. 2008. Speeding up the evaluation of new agents in cancer. Journal of the National Cancer Institute 100: 1204-1214.
7. Royston, P., F. M.-S. Barthel, M. K. B. Parmar, and B. C. Choodari-Oskooei. n.d. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of efficacy. Forthcoming.
8. Royston, P., M. K. B. Parmar, and W. Qian. 2003. Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Statistics in Medicine 22: 2239-2256.
9. Tsiatis, A. A. 1981. The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over time. Biometrika 68: 311-315.